- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01743638
MR-Guided Laser Ablation of Prostate Bed Recurrences
April 9, 2014 updated by: David A. Woodrum, Mayo Clinic
Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Prostate Bed Recurrences
The purpose of this study is to see if MR-guided laser ablation can effectively treat prostate tumor recurrences.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 95 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Patients with "biopsy proven" soft tissue tumor recurrences of prostate fossa referred to Urology and/or Interventional Radiology for treatment.
- Surgery is not a desirable alternative therapy at the time of enrollment
- Radiation therapy has failed or not indicated or can be safely postponed
- Tumor size ≤ 5 cm at its largest diameter
- Tumor does not encompass the rectal wall or external urethral sphincter
- Performance status is ECOG 2 or better in adults
- Patient is able to undergo MRI
Exclusion Criteria:
- Patients with pacemaker or defibrillator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: MR-Guided Laser Ablation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Measurement of target lesion(s) dimensions at 3-6 month imaging follow-up
Time Frame: 3-6 months
|
3-6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: David A. Woodrum, M.D., Ph.D., Mayo Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2012
Primary Completion (Actual)
February 1, 2014
Study Completion (Actual)
February 1, 2014
Study Registration Dates
First Submitted
December 4, 2012
First Submitted That Met QC Criteria
December 4, 2012
First Posted (Estimate)
December 6, 2012
Study Record Updates
Last Update Posted (Estimate)
April 10, 2014
Last Update Submitted That Met QC Criteria
April 9, 2014
Last Verified
April 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09-001584
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Tumors
-
Istituto Romagnolo per lo Studio dei Tumori Dino...CompletedProstate-specific Membrane Antigen | mCRPC or Advanced/Metastatic Solid TumorsItaly
-
University of Michigan Rogel Cancer CenterMerck Sharp & Dohme LLC; Hoosier Cancer Research NetworkActive, not recruitingNeuroendocrine Tumors | Prostate Cancer MetastaticUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma | Castration-Sensitive Prostate CarcinomaUnited States
-
AmgenCompletedCarcinoma | Cancer | Prostate Cancer | Tumors | Castrate-Resistant Prostate CancerUnited States, Canada, Poland, Hungary, Finland, Mexico
-
Fred Hutchinson Cancer CenterBristol-Myers SquibbWithdrawnStage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage III Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine CarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI); MultiFunctional Imaging LLCCompleted
-
Thomas HopeAbdera Therapeutics Inc.WithdrawnSolid Tumor Cancer | Castration Resistant Prostate Cancer | Castration Resistant Prostate Cancer (CRPC) | Neuroendocrine (NE) TumorsUnited States
-
Seoul National University HospitalUnknownProstate Cancer | Bladder Cancer | Bladder Tumor | Prostate Tumor
-
Sichuan Huiyang Life Science and Technology CorporationMedelis Inc.TerminatedMalignancies Including Melanoma, Kidney, Lung, Colorectal, Prostate, Neuroendocrine TumorUnited States
-
Affidea Nu-med Center of Oncological DIagnostics...RecruitingProstate Cancer (Adenocarcinoma) | Localized Prostate Cancer | Dose Escalation: Solid Tumors | Stereotactic Body Radiation Therapy (SBRT) | Prostate BrachytherapyPoland
Clinical Trials on MR-Guided Laser Ablation
-
Radboud University Medical CenterZiekenhuisgroep Twente; Canisius-Wilhelmina HospitalCompletedMRI | Prostate Cancer | Focal Laser AblationNetherlands
-
Urological Research Network, LLCRecruitingCancer of the Prostate | Neoplasms ProstateUnited States
-
MedtronicNeuroCompletedTemporal Lobe EpilepsyUnited States
-
BioTex, Inc.CompletedBrain Neoplasms | Brain Cancer | Brain Tumor | Recurrent Brain TumorFrance
-
HALO DiagnosticsActive, not recruiting
-
First Affiliated Hospital of Zhejiang UniversityUnknownRefractory NeoplasmsChina
-
First Affiliated Hospital of Zhejiang UniversityUnknownRefractory NeoplasmsChina
-
University of North Carolina, Chapel HillNational Institute of Neurological Disorders and Stroke (NINDS); University... and other collaboratorsRecruiting
-
Profound Medical Inc.CompletedProstate CancerUnited States, Canada, Germany
-
Clinical Laserthermia Systems ABCompleted